Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (261-270 of 418) with videos related to

Pageof 42
Sort By:
Journal of Drugs in Dermatology : JDD|May 19, 2005
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient creamDebra Breneman, Alan B Fleischer, David Kaplan, et al.
Journal of the American Academy of Dermatology|May 13, 2019
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedGrace Kimmel, Margot Chima, Hee Jin Kim, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
International Journal of Dermatology|April 14, 2015
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosisEggert Stockfleth, Ketty Peris, Carlos Guillen, et al.
Advances in Therapy|September 23, 2020
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in PsoriasisLinda Stein Gold, Javier Alonso-Llamazares, Jean-Philippe Lacour, et al.
Journal of Managed Care & Specialty Pharmacy|April 27, 2026
AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitisBridget Flavin, Denise Wolff, Mike Abdo, et al.
The British Journal of Dermatology|January 27, 2025
Efficacy of dupilumab for treatment-resistant Grover disease: a retrospective studyShivkar Amara, Kelly Hawkins, Elena Skaggs, et al.
BMJ Open|April 22, 2019
Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis RegistryBruce Strober, Jeffrey D Greenberg, Chitra Karki, et al.
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
Pageof 42

Showing results (261-270 of 418) with videos related to

Sort By:
Pageof 42
Journal of Drugs in Dermatology : JDD|May 19, 2005
Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient creamDebra Breneman, Alan B Fleischer, David Kaplan, et al.
Journal of the American Academy of Dermatology|May 13, 2019
Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failedGrace Kimmel, Margot Chima, Hee Jin Kim, et al.
Journal of Drugs in Dermatology : JDD|June 5, 2023
Integrating Precision Medicine into Medical Dermatology Clinical Practice: An Expert Consensus PanelDanny Zakria, Nicholas Brownstone, April W Armstrong, et al.
Journal of the American Academy of Dermatology|March 6, 2024
Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trialsAndrew Blauvelt, April Armstrong, Joseph F Merola, et al.
International Journal of Dermatology|April 14, 2015
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosisEggert Stockfleth, Ketty Peris, Carlos Guillen, et al.
Advances in Therapy|September 23, 2020
PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in PsoriasisLinda Stein Gold, Javier Alonso-Llamazares, Jean-Philippe Lacour, et al.
Journal of Managed Care & Specialty Pharmacy|April 27, 2026
AMCP Market Insights: Beyond skin deep on the role of managed care in moderate to severe atopic dermatitisBridget Flavin, Denise Wolff, Mike Abdo, et al.
The British Journal of Dermatology|January 27, 2025
Efficacy of dupilumab for treatment-resistant Grover disease: a retrospective studyShivkar Amara, Kelly Hawkins, Elena Skaggs, et al.
BMJ Open|April 22, 2019
Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis RegistryBruce Strober, Jeffrey D Greenberg, Chitra Karki, et al.
Clinical Immunology (Orlando, Fla.)|April 20, 2004
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B Gottlieb, Sewon Kang, Kenneth G Linden, et al.
Pageof 42